Insider Selling: NPS Pharmaceuticals CFO Sells 31,588 Shares of Stock (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) CFO Luke Beshar sold 31,588 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $35.01, for a total transaction of $1,105,895.88. Following the completion of the transaction, the chief financial officer now directly owns 59,180 shares of the company’s stock, valued at approximately $2,071,892. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) traded up 4.13% during mid-day trading on Thursday, hitting $36.56. 2,582,723 shares of the company’s stock traded hands. NPS Pharmaceuticals has a 52 week low of $7.35 and a 52 week high of $35.72. The stock’s 50-day moving average is $26.9 and its 200-day moving average is $25.1. The company’s market cap is $3.733 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $38.40 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $-0.21 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Brean Capital raised their price target on shares of NPS Pharmaceuticals from $36.00 to $41.00 in a research note to investors on Thursday. Separately, analysts at Canaccord Genuity raised their price target on shares of NPS Pharmaceuticals from $35.00 to $42.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of NPS Pharmaceuticals from $21.00 to $28.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. NPS Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $37.69.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.